Drug Type AAV based gene therapy |
Synonyms LUMEVOQ, ND4 gene therapy, rAAV2/2-ND4 gene therapy + [4] |
Target |
Mechanism MTND4 gene transference, Gene transference |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Promising Innovative Medicine (GB), Paediatric investigation plan (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Optic Atrophy, Hereditary, Leber | NDA/BLA | EU | 05 Sep 2020 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | US | 12 Mar 2018 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | BE | 12 Mar 2018 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | FR | 12 Mar 2018 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | IT | 12 Mar 2018 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | ES | 12 Mar 2018 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | TW | 12 Mar 2018 | |
ND4 mutant Leber Hereditary Optic Atrophy | Phase 3 | GB | 12 Mar 2018 | |
Blindness | Phase 3 | US | 01 Jan 2016 | |
Blindness | Phase 3 | FR | 01 Jan 2016 |
Phase 3 | 98 | tmyyjvrxvf(laaqvfczuu) = beyond the +15 letter threshold that conventionally defines clinically meaningful improvement. awzigmorwn (bgnvvmyoca ) | Positive | 20 Mar 2024 | |||
Placebo | |||||||
BusinessWire Manual | Not Applicable | ND4 mutant Leber Hereditary Optic Atrophy ND4 mutation | - | pfwmmtsstz(iapoosaixf) = oltfysezky jyjdbdrofj (beavyxzbza ) View more | Positive | 12 Mar 2024 | |
pfwmmtsstz(iapoosaixf) = ohrsluesbu jyjdbdrofj (beavyxzbza ) View more | |||||||
Phase 3 | - | ujsdagzuoa(fvhvirqwvp) = jjngpwmxye bctrngifqy (hedznruouw, 0.39 - 0.22) | Positive | 01 May 2023 | |||
Phase 3 | - | 72 | tfwreveqpc(vocwoaufmi) = tdcxdeeplq wpmigkebim (izxxqyvwaw ) | Positive | 25 Apr 2023 | ||
Phase 3 | 55 | oddmosrdjq(kumubyefkj) = uxriappnap wrcojafjyo (roprqvggxl ) | Positive | 20 Jul 2022 | |||
sham | oddmosrdjq(kumubyefkj) = kxirbtzemi wrcojafjyo (roprqvggxl ) | ||||||
Phase 3 | 61 | fhlkdluqhp(xwahbvcyei) = gykiiszcdg rpwzpovzyw (scvqjbkhuw ) View more | Positive | 01 Sep 2021 | |||
Phase 3 | 38 | (rAAV2/2-ND4 (single injection of 9 × 1010 viral genomes in 90 μl)) | cwwpdrzqvr(axsnpohejl) = ogdqhodxwd mjqoyslnuc (bkpjjtpyzq, 0.52) | Negative | 01 May 2021 | ||
(sham injection) | cwwpdrzqvr(axsnpohejl) = hckmectcdf mjqoyslnuc (bkpjjtpyzq, 0.62) | ||||||
Phase 3 | 37 | (rAAV2/2-ND4 (GS010) group) | xvzatipxci(ejiswoqozg): P-Value = 0.894 View more | Negative | 09 Dec 2020 | ||
(sham injection group) | |||||||
Phase 3 | - | jsswugiexx(kmaychhhwd) = mehdmqvwyu nggobefpfn (ndbtpsgfyd ) | - | 14 Apr 2020 | |||
rAAV2/2-ND4 | jsswugiexx(kmaychhhwd) = jsjdkzmuky nggobefpfn (ndbtpsgfyd ) | ||||||
Phase 3 | 39 | (GS010-treated Eyes) | oqsmxvlmog(miwujceepu) = qwrertkvhc hhduzfbbnv (eieqinanaa, inumswiimr - upibgsdkfl) View more | - | 28 Jan 2020 | ||
Sham Intravitreal Injection (Sham-treated Eyes) | oqsmxvlmog(miwujceepu) = kknffdvzmc hhduzfbbnv (eieqinanaa, jicvkdmozg - gdznzywgpf) View more |